Livzon Pharmaceutical Group Inc.

As China’s immuno-oncology market adapts to the ever-growing ranks of homegrown PD-1/L1-targeting agents, SinoCellTech has received approval for what will be the 17th product in the sector - but the f

A newly approved, homegrown once-weekly GLP-1 receptor agonist is seeking to disrupt a diabetes space in China currently dominated by Novo Nordisk’s same-class global blockbuster Ozempic (semaglutide)

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Citeline's Biomedtracker. Lotus Licenses Corium’s Alzh

Certa Therapeutics ’ lead candidate, FT011, has hit the mark in a Phase II scleroderma trial, sparking Phase III plans as the firm edges closer to validating its approach of targeting an undrugged rec